Effects of Qili Qiangxin capsules combined with Levosimendan in treatment of acute myocardial infarction complicated with heart failure
Objective:To observe effects of Qili Qiangxin capsules combined with Levosimendan in treatment of acute myocardial infarction complicated with heart failure.Methods:A prospective study was conducted on 110 patients with acute myocardial infarction complicated with heart failure admitted to the hospital from January 2022 to January 2023.According to the random number table method,they were divided into study group and control group,55 cases in each group.The control group was treated with Levosimendan,while the study group was treated with Qili Qiangxin capsules on the basis of that of the control group.The clinical efficacy,the serological indexes[soluble carcinogenic suppressor 2(sST2),matrix metalloproteinase-9(MMP-9)]levels,the cardiac function indexes[left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV),left ventricular ejection fraction(LVEF)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 94.55%(52/55),which was higher than 81.82%(45/55)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of sST2 and MMP-9 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The LVEF levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of LVESD and LVESV in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the study group was 9.09%(5/55),which was lower than 25.45%(14/55)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Qili Qiangxin capsules combined with Levosimendan in the treatment of the patients with acute myocardial infarction complicated with heart failure can improve the clinical efficacy,reduce the levels of sST2 and MMP-9,improve the cardiac function,and reduce the incidence of adverse reactions.Moreover,it is superior to single Levosimendan treatment.
Qili Qiangxin capsulesLevosimendanAcute myocardial infarctionHeart failureCardiac function
NETL
NSTL
万方数据
